These findings underscore the nuanced role of JNK signalling in ER+ breast cancer, where any deviation from normal/medium levels of JNK signalling, be it hyperactivation or suppression was associated with poor outcomes in ER+ breast cancer. This evidence concerns the gene MAPK8 and breast cancer.